Patient characteristics
Specimen . | Age/sex* . | WBC, ×109/L* . | Platelet count, ×109/L* . | Cytogenetics . | FA complementation group . | CD33† . | CD44† . | IL-3Rα† . |
---|---|---|---|---|---|---|---|---|
AML-1 | 12/F | 34 | 25 | 45, XX, −7 | A | 179 | 19 | 641 |
AML-2 | 9/M | 2.9 | 205 | 46, XY | A | 155 | 59 | 766 |
AML-3 | 11/M | 21 | 63 | 47, XY, +8, add(1q) | A | 169 | 37 | 690 |
AML-4 | 16/M | 0.1 | 39 | 45, XY, −7 | A | 181 | 75 | 750 |
AML-5 | 8/F | NA | NA | 45, XX, −7, add(3q) | C | 199 | 68 | 873 |
BMF-1 | 14/F | 4.3 | 110 | Normal | A | 222 | 39 | 64 |
BMF-2 | 13/F | 3.8 | 131 | Normal | A | 166 | 26 | 82 |
BMF-3 | 17/F | 2.3 | 79 | Normal | A | 158 | 47 | 30 |
BMF-4 | 10/M | 9.5 | 52 | Normal | A | 164 | 68 | 51 |
NBM-1 | 24/F | ND | ND | ND | N/A | 178 | 24 | 11 |
NBM-2 | 22/M | ND | ND | ND | N/A | 218 | 16 | 36 |
NBM-3 | 25/M | ND | ND | ND | N/A | 186 | 29 | 71 |
NBM-4 | 24/F | ND | ND | ND | N/A | 185 | 48 | 54 |
Specimen . | Age/sex* . | WBC, ×109/L* . | Platelet count, ×109/L* . | Cytogenetics . | FA complementation group . | CD33† . | CD44† . | IL-3Rα† . |
---|---|---|---|---|---|---|---|---|
AML-1 | 12/F | 34 | 25 | 45, XX, −7 | A | 179 | 19 | 641 |
AML-2 | 9/M | 2.9 | 205 | 46, XY | A | 155 | 59 | 766 |
AML-3 | 11/M | 21 | 63 | 47, XY, +8, add(1q) | A | 169 | 37 | 690 |
AML-4 | 16/M | 0.1 | 39 | 45, XY, −7 | A | 181 | 75 | 750 |
AML-5 | 8/F | NA | NA | 45, XX, −7, add(3q) | C | 199 | 68 | 873 |
BMF-1 | 14/F | 4.3 | 110 | Normal | A | 222 | 39 | 64 |
BMF-2 | 13/F | 3.8 | 131 | Normal | A | 166 | 26 | 82 |
BMF-3 | 17/F | 2.3 | 79 | Normal | A | 158 | 47 | 30 |
BMF-4 | 10/M | 9.5 | 52 | Normal | A | 164 | 68 | 51 |
NBM-1 | 24/F | ND | ND | ND | N/A | 178 | 24 | 11 |
NBM-2 | 22/M | ND | ND | ND | N/A | 218 | 16 | 36 |
NBM-3 | 25/M | ND | ND | ND | N/A | 186 | 29 | 71 |
NBM-4 | 24/F | ND | ND | ND | N/A | 185 | 48 | 54 |